Usp18 Expression in CD169(+) Macrophages is Important for Strong Immune Response after Vaccination with VSV-EBOV

Ebola virus epidemics can be effectively limited by the VSV-EBOV vaccine (Ervebo) due to its rapid protection abilities; however, side effects prevent the broad use of VSV-EBOV as vaccine. Mechanisms explaining the efficient immune activation after single injection with the VSV-EBOV vaccine remain m...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Vaccines (Basel)
Autors principals: Friedrich, Sarah-Kim, Schmitz, Rosa, Bergerhausen, Michael, Lang, Judith, Cham, Lamin B., Duhan, Vikas, Häussinger, Dieter, Hardt, Cornelia, Addo, Marylyn, Prinz, Marco, Asano, Kenichi, Lang, Philipp Alexander, Lang, Karl Sebastian
Format: Artigo
Idioma:Inglês
Publicat: MDPI 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7157200/
https://ncbi.nlm.nih.gov/pubmed/32210083
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/vaccines8010142
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars